Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Paul Hartmann AG's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 64.78.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Paul Hartmann AG's liquidation value for the
six
months ended in Jun. 2026 was €-358 Mil.
Paul Hartmann AG (FRA:PHH2) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Paul Hartmann AG's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG Change In Receivables Related Terms
Paul Hartmann AG Change In Receivables Historical Data
* Premium members only.
The historical data trend for Paul Hartmann AG's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG (FRA:PHH2) has a Change In Receivables of €0 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Paul Hartmann AG and its competitors.
Is Paul Hartmann AG's Change In Receivables too high?
Paul Hartmann AG's current Change In Receivables is €0 Mil. Overall, Paul Hartmann AG has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's Change In Receivables compare to ISRG and BDX?
Paul Hartmann AG's Change In Receivables of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Paul Hartmann AG and its competitors. Paul Hartmann AG's current Change In Receivables is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (FRA:PHH2) is currently considered Modestly Undervalued. The stock's GF Value™ is €226.94, compared to a current price of €201.00 — trading 11.4% below its estimated fair value. The current Change In Receivables is €0 Mil. Paul Hartmann AG's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Paul Hartmann AG (FRA:PHH2), the current Change In Receivables is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (FRA:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €201.00 is trading 11.4% below its estimated GF Value™ of €226.94.
GuruFocus considers Paul Hartmann AG to be Modestly Undervalued.
Key valuation signals for FRA:PHH2:
Change In Receivables: €0 Mil
GF Value™: €226.94 vs. price of €201.00 (11.4% below fair value)
No single metric tells the full story. See the FRA:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
64GF Score
Get the complete analysis for FRA:PHH2
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHH2 has been successfully added to your 
